Comparable stake leader
RA CAPITAL MANAGEMENT, L.P.
SEC ownership of ARS Pharmaceuticals, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001671858.
Disclosed value leader
James E. Flynn
Comparable rows
50/50
Latest evidence
31 Mar 2026
- Public ticker
- SPRY on Nasdaq
- Parsed ownership sources
- 13D/G, 3/4/5, and 13F
- Largest SEC-reported holder
- RA CAPITAL MANAGEMENT, L.P.
- Latest 13D/G holder
- RA CAPITAL MANAGEMENT, L.P.
- Latest parsed ownership date
- 31 Mar 2026
- Issuer CIK
- 0001671858
- Issuer location
- San Diego, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
2 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of ARS Pharmaceuticals, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
RA CAPITAL MANAGEMENT, L.P.
Disclosed value leader
James E. Flynn
Comparable rows
50/50
Latest evidence
31 Mar 2026
13D/G
3/4/5
13F
Lead comparable stake: 11%
13D/G row: RA CAPITAL MANAGEMENT, L.P.
Showing 1-8 of 50 holder rows.
Quick read
RA CAPITAL MANAGEMENT, L.P. leads the comparable SEC ownership view at 11%.
50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens RA CAPITAL MANAGEMENT, L.P.'s linked filing trail.
Comparable ownership
Top 5
RA CAPITAL MANAGEMENT, L.P.
11%
Rubric Capital Management LP
8.1%
James E. Flynn
7.8%
MILLENNIUM MANAGEMENT LLC
6%
BlackRock, Inc.
5%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 50 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. |
13D/G
3/4/5
13F
Director, 10%+ Owner · Company
|
11%
|
$111,050,917
10,940,977 shares
|
$0 | 29 Sep 2025 |
| Rubric Capital Management LP |
13D/G
13F
Company
|
8.1%
|
$64,400,000
8,000,000 shares
|
+$14,490,000 | 31 Mar 2026 |
| James E. Flynn |
3/4/5
13D/G
10%+ Owner · Deerfield Management Company, L.P.
|
7.8%
from 13D/G
|
$180,437,416
9,774,508 shares
|
-$13,663,151 | 27 Jun 2025 |
| MILLENNIUM MANAGEMENT LLC |
13D/G
13F
Company
|
6%
|
$48,748,087
5,916,030 shares
|
+$4,322,622 | 27 Mar 2026 |
| BlackRock, Inc. |
13F
13D/G
Company
|
5%
from 13D/G
|
$40,248,399
5,012,254 shares
|
— | 31 Mar 2026 |
| ORBIMED ADVISORS LLC |
13F
Company
|
8.4%
|
$66,556,735
8,288,510 shares
|
— | 31 Mar 2026 |
| DEERFIELD MANAGEMENT COMPANY, L.P. |
13F
Company
|
7.6%
|
$60,255,610
7,503,812 shares
|
— | 31 Mar 2026 |
| Aberdeen Group plc |
13F
Company
|
4.1%
|
$33,032,345
4,113,617 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to selling over the last 12 months. Net value: -$17,439,809.
Buys
$0
Insiders: 0
Sells
$17,439,809
Insiders: 7
Net
-$17,439,809
Shares: -1,070,857
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 1,070,857
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 188,208 | $0 | $1,666,197 | -$1,666,197 |
| 9-12 | 0 | 882,649 | $0 | $15,773,611 | -$15,773,611 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-20 of 30 reporting-owner rows connected to ARS Pharmaceuticals, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
30
Largest Forms 3/4/5 holder
Sarina Tanimoto
Net 12M change
-$17,439,809
Latest report
01 Jun 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Sarina Tanimoto | CHIEF MEDICAL OFFICER, 10%+ Owner | $203,017,758 | -$703,755 | -0.35% | Mixed | 02 Jan 2026 |
| Richard E. Lowenthal | PRESIDENT AND CEO, Director, 10%+ Owner | $202,790,460 | -$724,345 | -0.36% | Mixed | 02 Jan 2026 |
| James E. Flynn | 10%+ Owner | $180,437,416 | -$13,663,151 | -7% | Filing P/S | 27 Jun 2025 |
| Pratik Shah | Director | $44,969,267 | Mixed | 12 Nov 2025 | ||
| Laura Shawver | Director | $2,587,466 | Filing P/S | 25 Jun 2025 | ||
| Alexander A. Fitzpatrick | Chief Legal Officer | $1,263,238 | Filing P/S | 02 Jan 2026 | ||
| Kathleen D. Scott | Chief Financial Officer | $302,017 | -$187,500 | -38% | Mixed | 02 Jan 2026 |
| Jonathan Piazza | Chief Financial Officer | $261,878 | Mixed | 02 May 2022 | ||
| Valerie Odegard | President and CSO | $233,180 | Mixed | 02 May 2022 | ||
| Naomi Hunder | Chief Medical Officer | $205,897 | Mixed | 02 May 2022 | ||
| Jeffrey C. Pepe | Interim CEO and GC | $197,938 | Mixed | 02 Sep 2022 | ||
| Eric Karas | Chief Commercial Officer | $175,259 | -$494,861 | -74% | Filing P/S | 02 Jan 2026 |
| Russ Hawkinson | Sr. Vice President of Finance | $140,921 | Mixed | 02 May 2022 | ||
| Brian Dorsey | Chief Operating Officer | $93,936 | -$190,050 | -67% | Filing P/S | 02 Jan 2026 |
| Justin Chakma | Chief Business Officer | $0 | -$1,476,147 | -100% | Mixed | 02 Jan 2026 |
| Brent L. Saunders | Director | $0 | Mixed | 25 Jun 2025 | ||
| ORBIMED ADVISORS LLC | Director | $0 | Mixed | 26 Aug 2024 | ||
| Peter A. Thompson | Director | $0 | Mixed | 25 Jun 2025 | ||
| Donn Casale | President | Mixed | 01 Jun 2026 | |||
| Saqib Islam | Director | Mixed | 25 Jun 2025 |
Recent insider transactions for ARS Pharmaceuticals, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Kathleen D. Scott | SPRY | Stock option (right to buy) | Award | 240,000 | 240,000 | 02 Jan 2026 | Direct | |||
| Eric Karas | SPRY | Stock option (right to buy) | Award | 240,000 | 240,000 | 02 Jan 2026 | Direct | |||
| Alexander A. Fitzpatrick | SPRY | Stock option (right to buy) | Award | 240,000 | 240,000 | 02 Jan 2026 | Direct | |||
| Brian Dorsey | SPRY | Stock option (right to buy) | Award | 240,000 | 240,000 | 02 Jan 2026 | Direct | |||
| Justin Chakma | SPRY | Stock option (right to buy) | Award | 240,000 | 240,000 | 02 Jan 2026 | Direct | |||
| Sarina Tanimoto | SPRY | Stock Option (right to buy) | Award | 875,000 | 875,000 | 02 Jan 2026 | By Spouse | |||
| Sarina Tanimoto | SPRY | Stock option (right to buy) | Award | 240,000 | 240,000 | 02 Jan 2026 | Direct | |||
| Richard E. Lowenthal | SPRY | Stock Option (right to buy) | Award | 240,000 | 240,000 | 02 Jan 2026 | By Spouse | |||
| Richard E. Lowenthal | SPRY | Stock option (right to buy) | Award | 875,000 | 875,000 | 02 Jan 2026 | Direct | |||
| Brian Dorsey | SPRY | Common Stock | Sale | -66.9% | $190,050 | $8.71 | -21,828 | 10,789 | 13 Nov 2025 | Direct |
| Brian Dorsey | SPRY | Common Stock | Options Exercise | 202.3% | 21,828 | 32,617 | 13 Nov 2025 | Direct | ||
| Brian Dorsey | SPRY | Stock Option (Right to Buy) | Options Exercise | -100% | -21,828 | 0 | 13 Nov 2025 | Direct | ||
| Justin Chakma | SPRY | Common Stock | Sale | -100% | $1,476,147 | $8.87 | -166,380 | 0 | 12 Nov 2025 | Direct |
| Justin Chakma | SPRY | Common Stock | Options Exercise | 22% | 30,000 | 166,380 | 12 Nov 2025 | Direct | ||
| Justin Chakma | SPRY | Stock Option (Right to Buy) | Options Exercise | -25.2% | -30,000 | 89,047 | 12 Nov 2025 | Direct | ||
| Pratik Shah | SPRY | Common Stock | Gift | -7.25% | -350,000 | 4,474,554 | 12 Nov 2025 | By The Pratik Shah Living Trust dated June 15, 2011 | ||
| Richard E. Lowenthal | SPRY | Common Stock | Sale | -4.01% | $724,345 | $14.49 | -50,000 | 1,196,494 | 21 Aug 2025 | By Richard E. Lowenthal Charitable Remainder UniTrust Dated January 7, 2020 |
| Kathleen D. Scott | SPRY | Common Stock | Sale | -55.4% | $187,500 | $15.00 | -12,500 | 10,042 | 21 Aug 2025 | Direct |
| Kathleen D. Scott | SPRY | Common Stock | Options Exercise | 124.5% | 12,500 | 22,542 | 21 Aug 2025 | Direct | ||
| Kathleen D. Scott | SPRY | Stock Option (Right to Buy) | Options Exercise | -1.66% | -12,500 | 739,830 | 21 Aug 2025 | Direct | ||
| Sarina Tanimoto | SPRY | Common Stock | Sale | -2.93% | $530,626 | $14.09 | -37,656 | 1,247,447 | 20 Aug 2025 | By Sarina Tanimoto Charitable Remainder UniTrust Dated January 7, 2020 |
| Sarina Tanimoto | SPRY | Common Stock | Sale | -0.95% | $173,130 | $14.03 | -12,344 | 1,285,103 | 19 Aug 2025 | By Sarina Tanimoto Charitable Remainder UniTrust Dated January 7, 2020 |
| Eric Karas | SPRY | Common Stock | Sale | -59.2% | $254,860 | $16.99 | -15,000 | 10,315 | 01 Jul 2025 | Direct |
| Eric Karas | SPRY | Common Stock | Options Exercise | 145.4% | 15,000 | 25,315 | 01 Jul 2025 | Direct | ||
| Eric Karas | SPRY | Stock Option (Right to Buy) | Options Exercise | -2.68% | -15,000 | 544,588 | 01 Jul 2025 | Direct | ||
| James E. Flynn | SPRY | Class A Common Stock | Sale | -7.04% | $6,831,566 | $18.46 | -370,074 | 4,887,254 | 27 Jun 2025 | Through Deerfield Private Design Fund IV, L.P. |
| James E. Flynn | SPRY | Class A Common Stock | Sale | -7.04% | $6,831,584 | $18.46 | -370,075 | 4,887,254 | 27 Jun 2025 | Through Deerfield Private Design Fund III, L.P. |
| Ra Capital Management, L.P. | SPRY | Stock Option (Right to Buy) | Award | 30,000 | 30,000 | 25 Jun 2025 | See Footnotes | |||
| Rajeev Dadoo | SPRY | Stock Option (right to buy) | Award | 30,000 | 30,000 | 25 Jun 2025 | Direct | |||
| Pratik Shah | SPRY | Stock Option (right to buy) | Award | 30,000 | 30,000 | 25 Jun 2025 | Direct | |||
| Michael Kelly | SPRY | Stock Option (right to buy) | Award | 30,000 | 30,000 | 25 Jun 2025 | Direct | |||
| Saqib Islam | SPRY | Stock Option (right to buy) | Award | 30,000 | 30,000 | 25 Jun 2025 | Direct | |||
| Peter A. Thompson | SPRY | Stock Option (right to buy) | Award | 30,000 | 30,000 | 25 Jun 2025 | Direct | |||
| Brent L. Saunders | SPRY | Stock Option (right to buy) | Award | 30,000 | 30,000 | 25 Jun 2025 | Direct | |||
| Phillip M. Schneider | SPRY | Stock Option (right to buy) | Award | 30,000 | 30,000 | 25 Jun 2025 | Direct | |||
| Laura Shawver | SPRY | Stock Option (right to buy) | Award | 30,000 | 30,000 | 25 Jun 2025 | Direct | |||
| Eric Karas | SPRY | Common Stock | Sale | -66.1% | $240,000 | $16.00 | -15,000 | 7,696 | 18 Jun 2025 | Direct |
| Eric Karas | SPRY | Common Stock | Options Exercise | 194.9% | 15,000 | 22,696 | 18 Jun 2025 | Direct | ||
| Eric Karas | SPRY | Stock Option (Right to Buy) | Options Exercise | -2.61% | -15,000 | 559,588 | 18 Jun 2025 | Direct |
* marks a reported price that did not pass the local price check.